Anticorps anti-médicament, auto-anticorps et traitements biologiques du psoriasis
Author:
- 1 April 2012
- journal article
- abstracts
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 139, S58-S67
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseasesArthritis Research & Therapy, 2011
- Immunogénicité de protéines d’intérêt thérapeutiquemédecine/sciences, 2009
- Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodiesScandinavian Journal of Gastroenterology, 2009
- Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-α antibodiesClinical and Experimental Immunology, 2008
- Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s diseaseGut, 2007
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisArthritis & Rheumatism, 1998
- CD4 antibody treatment of severe psoriasisThe Lancet, 1991
- Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasisThe Lancet, 1991